Immix Biopharma (NASDAQ:IMMX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Immix Biopharma (NASDAQ:IMMX) from a hold rating to a sell rating in a report published on Saturday.

Several other equities analysts also recently weighed in on the stock. Mizuho initiated coverage on shares of Immix Biopharma in a report on Monday, February 9th. They set an “outperform” rating and a $14.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.00.

Immix Biopharma Stock Down 1.3%

IMMX stock opened at $7.33 on Friday. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $7.73. The stock has a market cap of $388.20 million, a P/E ratio of -9.52 and a beta of 0.31. The business’s 50-day moving average price is $5.77 and its 200-day moving average price is $3.91.

Institutional Trading of Immix Biopharma

A number of large investors have recently added to or reduced their stakes in IMMX. Allworth Financial LP bought a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $30,000. Velan Capital Investment Management LP bought a new stake in Immix Biopharma in the second quarter worth $52,000. Mathes Company Inc. purchased a new stake in Immix Biopharma during the fourth quarter valued at $56,000. Tocqueville Asset Management L.P. lifted its position in Immix Biopharma by 37.4% during the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after purchasing an additional 10,950 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Immix Biopharma during the fourth quarter valued at $112,000. Institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.